Targeting Wnt/β-catenin-mediated upregulation of oncogenic NLGN3 suppresses cancer stem cells in glioblastoma

Abstract Glioblastoma (GBM) is the most malignant tumor in brain and is highly resistant to therapy. Clinical evidence suggests increased number of cancer stem cells (CSCs) may contribute to the failure of conventional therapies, but the mechanisms associated with acquisition of CSC properties in GB...

Full description

Bibliographic Details
Main Authors: Eun-Jin Yun, Donghwi Kim, Sangwoo Kim, Jer-Tsong Hsieh, Seung Tae Baek
Format: Article
Language:English
Published: Nature Publishing Group 2023-07-01
Series:Cell Death and Disease
Online Access:https://doi.org/10.1038/s41419-023-05967-x
_version_ 1797778611408732160
author Eun-Jin Yun
Donghwi Kim
Sangwoo Kim
Jer-Tsong Hsieh
Seung Tae Baek
author_facet Eun-Jin Yun
Donghwi Kim
Sangwoo Kim
Jer-Tsong Hsieh
Seung Tae Baek
author_sort Eun-Jin Yun
collection DOAJ
description Abstract Glioblastoma (GBM) is the most malignant tumor in brain and is highly resistant to therapy. Clinical evidence suggests increased number of cancer stem cells (CSCs) may contribute to the failure of conventional therapies, but the mechanisms associated with acquisition of CSC properties in GBM are not fully understood. We found that DAB2IP suppresses CSC properties by targeting the synaptic proteins neuroligin 3 (NLGN3) in GBM. Furthermore, we showed that GBM-derived NLGN3 has an oncogenic function by inducing CSC properties within GBM. Moreover, elevated NLGN3 transcription mediated by Wnt/β-catenin signaling pathway resulted in increased secretion of NLGN3 into the surrounding tumor microenvironment. Both condition media containing NLGN3 and recombinant NLGN3 transformed neighboring cells to CSCs, suggesting NLGN3 as a critical component inducing CSC properties. Furthermore, targeting NLGN3-bearing CSCs using upstream Wnt/β-catenin inhibitors synergistically enhances the efficacy of conventional treatment. Hence, we unveiled the series of regulatory mechanisms for acquisition of CSC properties in GBM progression by Wnt/β-catenin-mediated NLGN3. These results may provide a new targeting strategy to improve the therapeutic efficacy of GBM treatments.
first_indexed 2024-03-12T23:19:56Z
format Article
id doaj.art-07b153b78bff4e7598f1b0ed3c5f83de
institution Directory Open Access Journal
issn 2041-4889
language English
last_indexed 2024-03-12T23:19:56Z
publishDate 2023-07-01
publisher Nature Publishing Group
record_format Article
series Cell Death and Disease
spelling doaj.art-07b153b78bff4e7598f1b0ed3c5f83de2023-07-16T11:29:44ZengNature Publishing GroupCell Death and Disease2041-48892023-07-0114711110.1038/s41419-023-05967-xTargeting Wnt/β-catenin-mediated upregulation of oncogenic NLGN3 suppresses cancer stem cells in glioblastomaEun-Jin Yun0Donghwi Kim1Sangwoo Kim2Jer-Tsong Hsieh3Seung Tae Baek4POSTECH Biotech Center, POSTECHDepartment of Life Sciences, POSTECHDepartment of Biomedical Systems Informatics and Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of MedicineDepartment of Biotechnology, Kaohsiung Medical UniversityDepartment of Life Sciences, POSTECHAbstract Glioblastoma (GBM) is the most malignant tumor in brain and is highly resistant to therapy. Clinical evidence suggests increased number of cancer stem cells (CSCs) may contribute to the failure of conventional therapies, but the mechanisms associated with acquisition of CSC properties in GBM are not fully understood. We found that DAB2IP suppresses CSC properties by targeting the synaptic proteins neuroligin 3 (NLGN3) in GBM. Furthermore, we showed that GBM-derived NLGN3 has an oncogenic function by inducing CSC properties within GBM. Moreover, elevated NLGN3 transcription mediated by Wnt/β-catenin signaling pathway resulted in increased secretion of NLGN3 into the surrounding tumor microenvironment. Both condition media containing NLGN3 and recombinant NLGN3 transformed neighboring cells to CSCs, suggesting NLGN3 as a critical component inducing CSC properties. Furthermore, targeting NLGN3-bearing CSCs using upstream Wnt/β-catenin inhibitors synergistically enhances the efficacy of conventional treatment. Hence, we unveiled the series of regulatory mechanisms for acquisition of CSC properties in GBM progression by Wnt/β-catenin-mediated NLGN3. These results may provide a new targeting strategy to improve the therapeutic efficacy of GBM treatments.https://doi.org/10.1038/s41419-023-05967-x
spellingShingle Eun-Jin Yun
Donghwi Kim
Sangwoo Kim
Jer-Tsong Hsieh
Seung Tae Baek
Targeting Wnt/β-catenin-mediated upregulation of oncogenic NLGN3 suppresses cancer stem cells in glioblastoma
Cell Death and Disease
title Targeting Wnt/β-catenin-mediated upregulation of oncogenic NLGN3 suppresses cancer stem cells in glioblastoma
title_full Targeting Wnt/β-catenin-mediated upregulation of oncogenic NLGN3 suppresses cancer stem cells in glioblastoma
title_fullStr Targeting Wnt/β-catenin-mediated upregulation of oncogenic NLGN3 suppresses cancer stem cells in glioblastoma
title_full_unstemmed Targeting Wnt/β-catenin-mediated upregulation of oncogenic NLGN3 suppresses cancer stem cells in glioblastoma
title_short Targeting Wnt/β-catenin-mediated upregulation of oncogenic NLGN3 suppresses cancer stem cells in glioblastoma
title_sort targeting wnt β catenin mediated upregulation of oncogenic nlgn3 suppresses cancer stem cells in glioblastoma
url https://doi.org/10.1038/s41419-023-05967-x
work_keys_str_mv AT eunjinyun targetingwntbcateninmediatedupregulationofoncogenicnlgn3suppressescancerstemcellsinglioblastoma
AT donghwikim targetingwntbcateninmediatedupregulationofoncogenicnlgn3suppressescancerstemcellsinglioblastoma
AT sangwookim targetingwntbcateninmediatedupregulationofoncogenicnlgn3suppressescancerstemcellsinglioblastoma
AT jertsonghsieh targetingwntbcateninmediatedupregulationofoncogenicnlgn3suppressescancerstemcellsinglioblastoma
AT seungtaebaek targetingwntbcateninmediatedupregulationofoncogenicnlgn3suppressescancerstemcellsinglioblastoma